Cetosomes® are synthetic, self-assembling nanovesicles made from cetylated fatty esters, with measured diameters of 60–850 nm and a claimed zeta potential of −20 to −100 mV. Exosomes are 30–150 nm vesicles released by living cells. For topical delivery, cetosomes have the edge in reproducibility, shelf stability and regulatory clarity. Exosome products face FDA safety warnings.
Two very different kinds of vesicle
The word "vesicle" covers particles with very different origins. A Cetosome® is engineered. Cetylated fatty esters, cetyl or stearyl alcohols, surfactants and polar solvents are combined under controlled heating and emulsification. On cooling they self-assemble into nanoparticles with a lamellar core and a charged outer corona.[1] An exosome is biological. It is a small extracellular vesicle released by living cells, carrying that cell's membrane proteins, lipids and nucleic acids.[2]
The difference matters for topical use. A delivery vehicle has to behave the same way in every batch, survive months on a shelf, and carry the active it was designed to carry. Engineering controls those properties. Biology adds variability.
Composition and what each vesicle carries
Cetosomes are defined by their components. The granted patent specifies a water phase of at least 40% of the composition, 4–20% of four or more cetylated or stearyl esters, cetyl or stearyl alcohols at a molar ratio to the esters of 1:3 or greater, 1–20% surfactant, and 2–30% polar solvent.[1] Actives are loaded by choice. Polar molecules associate with the solvent-rich mantle, and non-polar molecules partition into the lipid lamellae.
Exosomes carry whatever the parent cell put into them. Proteins, microRNA and lipids from the source cells define their cargo. That is why they interest regenerative medicine researchers, and it is also why they are hard to standardise. The International Society for Extracellular Vesicles' minimal-information guidelines (MISEV2018) exist because isolation methods, purity and characterisation differ so widely between laboratories.[2]
Size and size distribution
Exosomes generally fall in the 30–150 nm range. Cetosomes have measured diameters of 60–850 nm depending on formulation, and often show two populations. In one representative composition, analysed on a Zetasizer Nano ZS, the two populations measured 82.6 ± 15.8 nm and 845.7 ± 114.4 nm.[1] The patent attributes the larger population to vesicles built around an oil or non-polar core.
Smaller is not automatically better for skin. Particle size and polydispersity determine where a lipid nanocarrier goes and how consistently it does so.[4] The stratum corneum blocks most molecules above roughly 500 Da,[6] so the useful questions are whether the carrier releases its cargo at the right place and whether it does so reproducibly.
Shelf stability
Property | Cetosomes® | Exosomes (topical products) |
|---|---|---|
Origin | Synthetic self-assembly | Cell-derived (human, animal or plant) |
Zeta potential | −20 to −100 mV claimed; −22 to −55 mV measured across formulations | Typically modestly negative; varies with source and isolation method |
Real-time stability | 18–26 months reported at 25 °C / 65% RH | Usually needs cold chain or lyophilisation; data rarely published |
Batch definition | Specified by composition ratios | Defined by source cells and isolation protocol |
The cetosome stability figures come from the patent's real-time studies, which tracked nanoparticle integrity and active concentration. One composition was stable for 26 months, another for 18 months, and a third passed both real-time and accelerated (40 °C / 75% RH) testing for up to 6 months.[1] Stability is attributed partly to a strongly negative zeta potential that keeps the particles from flocculating.
Regulatory status
This is where the two diverge most. The US Food and Drug Administration has issued a public safety notification stating that no exosome products are approved for treatment. It warns that unapproved products marketed this way have caused serious adverse events.[3] The notice covers human-derived products for injection and therapeutic use, but it shapes how regulators and clinicians view the whole category.
Many cosmetic "exosome" ingredients are plant-derived or synthetic vesicles that cannot carry the biological signals marketing implies. Cetosomes are an excipient platform, a vehicle chemistry built from compounds familiar in pharmaceutical and cosmetic formulation, and the active is chosen separately.
Evidence on delivery
Lipid vesicles have been studied for skin delivery for more than three decades. The evidence is clear that vesicle composition, not the vesicle label, determines outcome.[5] Cetosomes have a documented mechanism: they move through the stratum corneum without permanently disrupting barrier function, then break into smaller penetration units that release their cargo gradually.[1] Exosome topical data are mostly preclinical, and few studies separate the vesicle's own biological effect from its function as a carrier.
Verdict for formulators and clinicians
Choose exosomes if you are researching biology. Choose an engineered nanovesicle if you need a vehicle.
For delivering a defined active, such as azelaic acid, a retinoid, niacinamide or a follicular drug, the deciding factors are reproducibility, stability, regulatory clarity and tolerability. On every one of those, the published characterisation of cetosomes is more complete than anything currently available for topical exosome products.
Frequently asked
Are exosomes better than cetosomes for skin?
Not for vehicle performance. Exosomes are biologically active cell-derived vesicles that are difficult to standardise and are under FDA safety warning for unapproved human-derived products. Cetosomes are synthetic, reproducible carriers with patent-documented size, charge and multi-month stability data, which makes them more predictable as a topical delivery system.
What size are cetosomes compared with exosomes?
Exosomes are typically about 30–150 nm. Cetosomes have measured diameters of 60–850 nm depending on composition, often with two populations: a smaller one of around 60–100 nm and a larger, oil-loaded one of up to about 850 nm.
Are exosome skincare products regulated?
In the United States, the FDA has stated that no exosome products are approved for treatment and has warned the public about unapproved exosome products. Many cosmetic ‘exosome’ ingredients are plant-derived or synthetic vesicle-like particles rather than human cell-derived exosomes.
References
- Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles 7(1):1535750. 2018.DOI 10.1080/20013078.2018.1535750
- US Food and Drug Administration, Center for Biologics Evaluation and Research. Public Safety Notification on Exosome Products. FDA Safety & Availability (Biologics). 2019.
- Danaei M, Dehghankhold M, Ataei S, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 10(2):57. 2018.DOI 10.3390/pharmaceutics10020057
- Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics 332(1–2):1–16. 2007.DOI 10.1016/j.ijpharm.2006.12.005
- Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
Methodology
Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.
Conflict of interest & scope
Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.